Equifax (EFX) Tops Q4 EPS by 7c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- SpaceX slides, tech stocks dip — what’s moving markets
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Equifax (EFX) Declares $0.39 Quarterly Dividend; 1.4% Yield
March 1, 2018 5:06 PM ESTEquifax (NYSE: EFX) declared a quarterly dividend of $0.39 per share, or $1.56 annualized.
The dividend will be payable on March 30, 2018, to stockholders of record on March 12, 2018, with an ex-dividend date of March 9, 2018.
The annual yield on the dividend is 1.4 percent.
For a... More
Equifax profit beats Street view as breach costs climb
March 1, 2018 9:21 AM ESTBy Jim Finkle and Aparajita Saxena
(Reuters) - Equifax Inc (NYSE: EFX) on Thursday reported quarterly results ahead of Wall Street forecasts, even as the consumer credit agency posted $26.5 million in costs related to last year's massive data breach.
The company posted quarterly per-share profit of $1.39, beating the average analyst forecast of $1.35, according to Thomson Reuters I/B/E/S. Revenue rose 5 percent from a year earlier to $838.5 million, beating the average forecast of $825.7 million.
Equifax disclosed earlier... More
Why Oppenheimer Global fund is focusing on biotech as rates rise
February 27, 2018 11:02 PM ESTBy David Randall
NEW YORK (Reuters) - The recent volatility in the global stock market may make some investors feel queasy, but it is providing a buying opportunity in biotechnology stocks.
That is because biotechs will see little impact from rising interest rates because investors are more focused on the long-term potential of their drugs, said Rajeev Bhaman, portfolio manager of the $11.8 billion Oppenheimer Global fund.
Bhaman, whose fund received a 2018 U.S. Thomson Reuters Lipper Fund Award in the global large-cap growth fund category in New York on Tuesday, is focusing on companies such as Sage... More
